Provided by Tiger Trade Technology Pte. Ltd.

Amgen

421.51
-2.1300-0.50%
Pre-market: 418.97-2.5400-0.60%07:15 EDT
Volume:3.13M
Turnover:1.32B
Market Cap:226.97B
PE:26.18
High:426.59
Open:424.01
Low:420.63
Close:423.64
52wk High:447.03
52wk Low:283.00
Shares:538.48M
Float Shares:536.99M
Volume Ratio:1.10
T/O Rate:0.58%
Dividend:9.80
Dividend Rate:2.32%
EPS(TTM):16.10
EPS(LYR):14.23
ROE:91.47%
ROA:8.67%
PB:19.42
PE(LYR):29.62

Loading ...

Amgen - Phase 3 Dellphi-305 Study Delivers Significant Overall Survival Benefit Versus Durvalumab Alone

THOMSON REUTERS
·
Sep 08

Imdelltra® in Combination with Imfinzi® Demonstrated Landmark Improvement in Overall Survival in First-Line Extensive Stage Small Cell Lung Cancer

THOMSON REUTERS
·
Sep 08

Amgen - Study Meets Secondary Endpoints for Progression-Free Survival and Objective Response Rate

THOMSON REUTERS
·
Sep 08

Amgen - no New or Unexpected Safety Signals Identified in Dellphi-305 Study

THOMSON REUTERS
·
Sep 08

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Guardant Health (GH) and Neurocrine (NBIX)

TIPRANKS
·
Sep 08

Political and General News Events from September 8

Reuters
·
Sep 08

【US Pre-Market】Middle East Energy Risks Escalate, Brent Crude Nears $100, Oil and Gas Stocks Rise; Novartis Plunges 13%

TradingKey
·
Sep 08

Amgen Price Target Maintained with a $400.00/Share by Cantor Fitzgerald

Dow Jones
·
Sep 08

Intel, Amgen, Novartis, Bloom Energy, and More Stocks That Explain Today's Market

Dow Jones
·
Sep 08

Beneath the Surface, the Next Market Leaders are Getting Ready to Break Out, Says Morgan Stanley

Dow Jones
·
Sep 08

Ionis Pharma Tumbles After Heart Drug Fails Late-Stage Trial

Reuters
·
Sep 08

Rothschild & Co Redburn Adjusts Price Target on Amgen to $225 From $235, Keeps Sell Rating

MT Newswires Live
·
Sep 08

Why Amgen Stock is Dropping After Swiss Rival's Trial Setback

Dow Jones
·
Sep 08

Amgen Falls After Novartis Trial Setback, BMO Downgrade

Reuters
·
Sep 08

Stocks to Watch: Amgen, Nike, Bloom Energy

Dow Jones
·
Sep 08

Amgen downgraded to Market Perform from Outperform at BMO Capital

TIPRANKS
·
Sep 08

Amgen Shares Down 5.4% Premarket; Rival Novartis Cholesterol Drug Fails Late-Stage Study

THOMSON REUTERS
·
Sep 08

Why the Dow is Being Dragged Down by a Swiss Company's Bad News

Dow Jones
·
Sep 08

Movement Alert|Amgen Falls 5.08% in Pre-Market Trading, Novartis Lp(a) Heart Drug Phase III Failure Drags Down Peer Stocks

Market Focus
·
Sep 08

Movement Alert|Amgen Overnight Decline 5.27%, Dragged by Novartis Lp(a) Drug Trial Failure Casting Doubt on Cardiovascular Pipeline Thesis

Market Focus
·
Sep 08